Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Simplify Asset Management Inc.

Simplify Asset Management Inc. cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,224 shares of the medical research company’s stock after selling 47 shares during the period. Thermo Fisher Scientific comprises about 0.3% of Simplify Asset Management Inc.’s holdings, making the stock its 27th largest position. Simplify Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $4,548,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in TMO. Accretive Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 8.1% in the 4th quarter. Accretive Wealth Partners LLC now owns 640 shares of the medical research company’s stock valued at $340,000 after buying an additional 48 shares in the last quarter. Aveo Capital Partners LLC lifted its position in Thermo Fisher Scientific by 9.7% in the fourth quarter. Aveo Capital Partners LLC now owns 816 shares of the medical research company’s stock valued at $433,000 after acquiring an additional 72 shares during the last quarter. Gryphon Financial Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 8.5% during the fourth quarter. Gryphon Financial Partners LLC now owns 1,484 shares of the medical research company’s stock worth $794,000 after purchasing an additional 116 shares during the last quarter. TrinityPoint Wealth LLC increased its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. TrinityPoint Wealth LLC now owns 4,080 shares of the medical research company’s stock worth $2,166,000 after purchasing an additional 164 shares in the last quarter. Finally, Frazier Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $49,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 860 shares of the business’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the transaction, the chief accounting officer now directly owns 1,814 shares of the company’s stock, valued at $1,108,408.42. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the transaction, the executive vice president now owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 860 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the sale, the chief accounting officer now directly owns 1,814 shares of the company’s stock, valued at approximately $1,108,408.42. The disclosure for this sale can be found here. Insiders sold 23,084 shares of company stock worth $14,094,292 in the last ninety days. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $620.26 on Friday. The company has a market cap of $236.94 billion, a price-to-earnings ratio of 39.79, a PEG ratio of 2.86 and a beta of 0.78. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The firm has a 50 day moving average of $598.25 and a 200-day moving average of $581.25. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter last year, the business posted $5.15 earnings per share. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TMO shares. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Wells Fargo & Company initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price target for the company. Stifel Nicolaus lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. TD Cowen increased their target price on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, Robert W. Baird increased their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $632.89.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.